Shandong Xinhua Pharmaceutical (SHE:000756, HKG:0719) obtained drug registration from China's drug regulator for ambroxol hydrochloride and clenbuterol hydrochloride oral solution.
The drug treats cough, viscous sputum, expectoration difficulty and wheezing from bronchitis, emphysema and other respiratory diseases, according to a Tuesday filing with the Shenzhen bourse.
Shares of the pharmaceutical company were down 3% on the Shenzhen bourse and 1% on the Hong Kong bourse.
Cranex (BOM:522001) bagged an order worth nearly 20 million Indian rupees from Integral Coach Factory Chennai, according to a BSE filing on Tuesday.The contract is for the manufacturing and supply of a 40T electric overhead traveling crane with lifting tackle.The cranes will be delivered by Jan. 30, 2027.The company's shares were up over 5% in recent trade.
Park Medi World's (NSE:PARKHOSPS, BOM:544645) consolidated attributable profit rose to 708.6 million Indian rupees in the fiscal fourth quarter ended March 31, from 448.4 million rupees a year ago.Earnings per share came in at 1.78 rupees from 1.36 rupees a year earlier, the healthcare services company said in a filing to the Indian stock exchanges on Tuesday.Revenue from operations in fiscal Q4 also increased to 4.60 billion rupees from 3.54 billion rupees a year ago.The company's shares were down nearly 2% in recent trade.
BASE (TYO:4477) extended the effective period of its confidentiality agreement with shareholder Hiroyuki Maki by an additional three months as the company continues friendly engagement discussions aimed at enhancing corporate value and shareholder interests, according to a Tuesday filing on the Tokyo Stock Exchange.The extension brings the agreement period to one year from its original execution date in August 2025. No other terms of the agreement were changed.BASE said it will continue discussions with Maki and pursue initiatives aimed at strengthening corporate value and the common interests of shareholders. The company first entered into the confidentiality agreement in August 2025 alongside the abolition of its anti-takeover policy framework.